Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The vasoactive intestinal peptide analogue RO25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes.

× No keyword cloud information.

11 in total

Review 1. IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: regulation of T helper 1/T helper 2 responses.

Authors: G Haskó; C Szabó
Journal: Br J Pharmacol Date: 1999-07 Impact factor: 8.739

2. Pituitary adenylate cyclase-activating peptide receptor 1 mediates anti-inflammatory effects in allergic airway inflammation in mice.

Authors: H D Lauenstein; D Quarcoo; L Plappert; C Schleh; M Nassimi; C Pilzner; S Rochlitzer; P Brabet; T Welte; H G Hoymann; N Krug; M Müller; E A Lerner; A Braun; D A Groneberg
Journal: Clin Exp Allergy Date: 2010-11-09 Impact factor: 5.018

3. Dual bronchodilatory and pulmonary anti-inflammatory activity of RO5024118, a novel agonist at vasoactive intestinal peptide VPAC2 receptors.

Authors: S A Tannu; L M Renzetti; N Tare; J D Ventre; D Lavelle; T A Lin; A Morschauser; J Paciorek; D R Bolin; H Michel; L Singer; M Hargaden; Id Knowles; P Gardiner; M Cazzola; L Calzetta; M G Matera; A Hicks
Journal: Br J Pharmacol Date: 2010-11 Impact factor: 8.739

4. Bronchodilation by an inhaled VPAC(2) receptor agonist in patients with stable asthma.

Authors: A Lindén; L Hansson; A Andersson; M Palmqvist; P Arvidsson; C-G Löfdahl; P Larsson; J Lötvall
Journal: Thorax Date: 2003-03 Impact factor: 9.139

Review 5. Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease.

Authors: S G R Smalley; P A Barrow; N Foster
Journal: Clin Exp Immunol Date: 2009-08 Impact factor: 4.330

6. VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses.

Authors: Yossan-Var Tan; Catalina Abad; Yuqi Wang; Robert Lopez; James Waschek
Journal: Brain Behav Immun Date: 2014-10-13 Impact factor: 7.217

The vasoactive intestinal peptide analogue RO25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes.

Review 1. IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: regulation of T helper 1/T helper 2 responses.

2. Pituitary adenylate cyclase-activating peptide receptor 1 mediates anti-inflammatory effects in allergic airway inflammation in mice.

3. Dual bronchodilatory and pulmonary anti-inflammatory activity of RO5024118, a novel agonist at vasoactive intestinal peptide VPAC2 receptors.

4. Bronchodilation by an inhaled VPAC(2) receptor agonist in patients with stable asthma.

Review 5. Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease.

6. VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses.

Review 7. Direct and indirect antimicrobial activities of neuropeptides and their therapeutic potential.

8. Vasodilatory effect of the stable vasoactive intestinal peptide analog RO 25-1553 in murine and rat lungs.

9. Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis.

Review 10. The Neuromodulation of the Intestinal Immune System and Its Relevance in Inflammatory Bowel Disease.